Yu-Lin Chang

发表

Long-term experience with testosterone replacement through scrotal skin

P. Snyder, E. AtkinsonLinda, Yu-Lin Chang, 1998 .

Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

P. Hari, P. Moreau, P. Voorhees, 2019, Leukemia research.

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.

R. Rifkin, J. Berenson, J. Shah, 2019, Clinical lymphoma, myeloma & leukemia.

Metastatic lung neuroendocrine carcinoma presenting as a breast lump

W. Kang, S. Tsao, Yu-Lin Chang, 2019, Formosan Journal of Surgery.

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

R. Rifkin, J. Berenson, J. Shah, 2015 .

Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.

J. Cortes, J. Kolitz, J. Lancet, 2020 .

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

R. Salazar, E. Van Cutsem, J. Tabernero, 2013, Clinical Cancer Research.

Ischemic Colitis Following Colonoscopy in an Elder Patient with Cardiovascular Disease

M. Tsai, Yu-Lin Chang, 2015 .

Multiple Tumors of the Follicular Infundibulum

Shu-ling Hu, Yih-Yiing Wu, Yu-Lin Chang, 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

M. Burotto, R. Motzer, T. Powles, 2023, The New England journal of medicine.

Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.

R. Motzer, T. Powles, T. Choueiri, 2023, Journal of Clinical Oncology.

Cecal Cancer Associated with Distal Ileal Thickening: Report of a Case and Its Clinical Significance

W. Kang, H. Chiu, Yu-Lin Chang, 2010 .

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .